Stocktoria

NovaBridge Biosciences NBP

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-01-17

NovaBridge Biosciences statistics & valuation

Market cap$189.2M
P / B0.8×
Return on equity-20.0%
Return on capital-40.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20182019202020212022202320242025
Operating margin (%)
-11395.10% 20182019202020212022202320242025
Return on equity (%)
8.40% -51.20% -88.80% -85.60% -11.10% -20.00% 20182019202020212022202320242025
Shares outstanding
8.4M 133.0M 164.9M 183.8M 190.9M 191.4M 187.5M 265.4M 20182019202020212022202320242025
Net debt ($)
20182019202020212022202320242025
Share buybacks ($)
20182019202020212022202320242025
Return on assets (%)
-17.00% -83.60% 7.40% -41.60% -62.80% -56.30% -10.50% -17.80% 20182019202020212022202320242025
Free cash flow margin (%)
-548.70% -2934.20% 4.20% -178.80% -29107.90% 20182019202020212022202320242025
Debt / equity (×)
20182019202020212022202320242025
EPS ($)
-$61.70 -$28.90 $0.46 -$2.09 -$1.96 -$1.09 -$0.12 -$0.21 20182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin——-11395.1%3422.2%————
Net margin——-32868.5%23923.5%-415.6%4.7%-4840.1%-749.0%
FCF margin——-29107.9%10443.8%-178.8%4.2%-2934.2%-548.7%
Return on assets-17.8%-10.5%-56.3%-62.8%-41.6%7.4%-83.6%-17.0%
Return on equity-20.0%-11.1%-85.6%-88.8%-51.2%8.4%71.4%42.2%
Current ratio8.0920.905.674.787.669.282.315.88

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.